Do analysts prefer COG or RENX?

Cambridge Cognition currently has a consensus target price of GBX 56, indicating a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, research analysts plainly believe Cambridge Cognition is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer INHC or COG?

Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Induction Healthcare Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Induction Healthcare Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate COG or FDBK?

Cambridge Cognition presently has a consensus target price of GBX 56, suggesting a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, equities analysts plainly believe Cambridge Cognition is more favorable than Feedback. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Feedback 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer IQAI or COG?

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than IQ-AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IQ-AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, IQAI or COG?

IQ-AI has higher earnings, but lower revenue than Cambridge Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQ-AI £538.19K 3.30 N/A N/A N/A Cambridge Cognition £9.40M 1.95 -£1.58M -£3.90 N/A

Is IQAI or COG more profitable?

Cambridge Cognition has a net margin of -17.82% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -62.89% beat IQ-AI's return on equity. Company Net Margins Return on Equity Return on Assets IQ-AI -77.52% -140.75% -22.03% Cambridge Cognition -17.82% -62.89% -0.30%

Cambridge Cognition (COG) Competitors

GBX 34 +1.00 (+3.03%)

As of 10:32 AM Eastern

Compare

COG vs. KOO, RENX, INHC, FDBK, and IQAI

Should you buy Cambridge Cognition stock or one of its competitors? MarketBeat compares Cambridge Cognition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cambridge Cognition include Kooth (KOO), Renalytix (RENX), Induction Healthcare Group (INHC), Feedback (FDBK), and IQ-AI (IQAI).

How does Cambridge Cognition compare to Kooth?

Cambridge Cognition (LON:COG) and Kooth (LON:KOO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Kooth had 2 more articles in the media than Cambridge Cognition. MarketBeat recorded 2 mentions for Kooth and 0 mentions for Cambridge Cognition. Kooth's average media sentiment score of 0.21 beat Cambridge Cognition's score of 0.00 indicating that Kooth is being referred to more favorably in the news media.

Company	Overall Sentiment
Cambridge Cognition	Neutral
Kooth	Neutral

Cambridge Cognition presently has a consensus target price of GBX 56, indicating a potential upside of 64.71%. Kooth has a consensus target price of GBX 330, indicating a potential upside of 122.97%. Given Kooth's higher probable upside, analysts clearly believe Kooth is more favorable than Cambridge Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kooth has a net margin of 4.12% compared to Cambridge Cognition's net margin of -17.82%. Kooth's return on equity of 8.84% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-17.82%	-62.89%	-0.30%
Kooth	4.12%	8.84%	10.12%

Cambridge Cognition has a beta of 0.809, indicating that its share price is 19% less volatile than the broader market. Comparatively, Kooth has a beta of 1.286, indicating that its share price is 29% more volatile than the broader market.

Kooth has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.95	-£1.58M	-£3.90	N/A
Kooth	£63.29M	0.85	£4.00M	£7.00	21.14

15.9% of Cambridge Cognition shares are held by institutional investors. Comparatively, 21.0% of Kooth shares are held by institutional investors. 2.8% of Cambridge Cognition shares are held by insiders. Comparatively, 30.4% of Kooth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Kooth beats Cambridge Cognition on 14 of the 15 factors compared between the two stocks.

How does Cambridge Cognition compare to Renalytix?

Cambridge Cognition (LON:COG) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Cambridge Cognition has a net margin of -17.82% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-17.82%	-62.89%	-0.30%
Renalytix	-506.25%	675.00%	-93.54%

Cambridge Cognition has a beta of 0.809, meaning that its share price is 19% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

15.9% of Cambridge Cognition shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 2.8% of Cambridge Cognition shares are owned by company insiders. Comparatively, 5.1% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.95	-£1.58M	-£3.90	N/A
Renalytix	£3.30M	4.14	-£109.93M	-£4.00	N/A

In the previous week, Cambridge Cognition's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company	Overall Sentiment
Cambridge Cognition	Neutral
Renalytix	Neutral

Cambridge Cognition currently has a consensus target price of GBX 56, indicating a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, research analysts plainly believe Cambridge Cognition is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cambridge Cognition beats Renalytix on 9 of the 14 factors compared between the two stocks.

How does Cambridge Cognition compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Induction Healthcare Group has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, indicating that its share price is 19% less volatile than the broader market.

In the previous week, Induction Healthcare Group's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company	Overall Sentiment
Induction Healthcare Group	Neutral
Cambridge Cognition	Neutral

Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Induction Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Induction Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cambridge Cognition has a net margin of -17.82% compared to Induction Healthcare Group's net margin of -23.86%. Induction Healthcare Group's return on equity of -14.58% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Induction Healthcare Group	-23.86%	-14.58%	-7.32%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Cambridge Cognition has lower revenue, but higher earnings than Induction Healthcare Group. Cambridge Cognition is trading at a lower price-to-earnings ratio than Induction Healthcare Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A
Cambridge Cognition	£9.40M	1.95	-£1.58M	-£3.90	N/A

46.3% of Induction Healthcare Group shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 54.6% of Induction Healthcare Group shares are owned by company insiders. Comparatively, 2.8% of Cambridge Cognition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Cambridge Cognition beats Induction Healthcare Group on 9 of the 14 factors compared between the two stocks.

How does Cambridge Cognition compare to Feedback?

Cambridge Cognition (LON:COG) and Feedback (LON:FDBK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Cambridge Cognition presently has a consensus target price of GBX 56, suggesting a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, equities analysts plainly believe Cambridge Cognition is more favorable than Feedback.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Feedback	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cambridge Cognition has higher revenue and earnings than Feedback. Cambridge Cognition is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.95	-£1.58M	-£3.90	N/A
Feedback	£849.62K	3.15	-£10.84M	-£15.74	N/A

Cambridge Cognition has a net margin of -17.82% compared to Feedback's net margin of -845.25%. Cambridge Cognition's return on equity of -62.89% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-17.82%	-62.89%	-0.30%
Feedback	-845.25%	-135.17%	-22.99%

Cambridge Cognition has a beta of 0.809, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Feedback has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

15.9% of Cambridge Cognition shares are owned by institutional investors. Comparatively, 34.2% of Feedback shares are owned by institutional investors. 2.8% of Cambridge Cognition shares are owned by company insiders. Comparatively, 8.0% of Feedback shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cambridge Cognition's average media sentiment score of 0.00 equaled Feedback'saverage media sentiment score.

Company	Overall Sentiment
Cambridge Cognition	Neutral
Feedback	Neutral

Summary

Cambridge Cognition beats Feedback on 10 of the 14 factors compared between the two stocks.

How does Cambridge Cognition compare to IQ-AI?

IQ-AI (LON:IQAI) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than IQ-AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQ-AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

IQ-AI has higher earnings, but lower revenue than Cambridge Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQ-AI	£538.19K	3.30	N/A	N/A	N/A
Cambridge Cognition	£9.40M	1.95	-£1.58M	-£3.90	N/A

15.9% of Cambridge Cognition shares are held by institutional investors. 66.0% of IQ-AI shares are held by insiders. Comparatively, 2.8% of Cambridge Cognition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cambridge Cognition has a net margin of -17.82% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -62.89% beat IQ-AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQ-AI	-77.52%	-140.75%	-22.03%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

In the previous week, IQ-AI's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company	Overall Sentiment
IQ-AI	Neutral
Cambridge Cognition	Neutral

IQ-AI has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, indicating that its stock price is 19% less volatile than the broader market.

Summary

Cambridge Cognition beats IQ-AI on 9 of the 12 factors compared between the two stocks.

Get Cambridge Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COG vs. The Competition

Export

Metric	Cambridge Cognition	Healthcare Technology Industry	Healthcare Sector	LON Exchange
Market Cap	£18.30M	£1.43B	£6.91B	£2.87B
Dividend Yield	N/A	4.74%	2.60%	6.13%
P/E Ratio	-8.72	275.93	281.39	369.23
Price / Sales	1.95	65.04	573.11	83,859.34
Price / Cash	4.31	30.98	71.79	27.89
Price / Book	4.68	4.93	12.91	7.08
Net Income	-£1.58M	-£25.90M	£3.49B	£5.89B
7 Day Performance	0.92%	4.58%	2.63%	1.25%
1 Month Performance	-0.73%	-1.30%	-2.72%	0.98%
1 Year Performance	37.21%	-18.70%	75.99%	75.29%

Cambridge Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COG Cambridge Cognition	N/A	GBX 34 +3.0%	GBX 56 +64.7%	+28.2%	£18.30M	£9.40M	N/A	80	Gap Up
KOO Kooth	2.7186 of 5 stars	GBX 156 -0.3%	GBX 330 +111.5%	-4.0%	£56.58M	£63.29M	22.29	478
RENX Renalytix	N/A	GBX 2.57 -3.1%	N/A	-56.0%	£11.58M	£3.30M	N/A	102
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+0.0%	£9.00M	£12.57M	N/A	74
FDBK Feedback	N/A	GBX 6.13 -0.4%	N/A	-56.8%	£2.68M	£849.62K	N/A	24

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:COG) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cambridge Cognition (COG) Competitors

COG vs. KOO, RENX, INHC, FDBK, and IQAI

How does Cambridge Cognition compare to Kooth?

Summary

How does Cambridge Cognition compare to Renalytix?

Summary

How does Cambridge Cognition compare to Induction Healthcare Group?

Summary

How does Cambridge Cognition compare to Feedback?

Summary

How does Cambridge Cognition compare to IQ-AI?

Summary

Media Sentiment Over Time

COG vs. The Competition

Cambridge Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cambridge Cognition (COG) Competitors

COG vs. KOO, RENX, INHC, FDBK, and IQAI

How does Cambridge Cognition compare to Kooth?

Does the media refer more to COG or KOO?

Do analysts rate COG or KOO?

Is COG or KOO more profitable?

Which has more volatility & risk, COG or KOO?

Which has better valuation and earnings, COG or KOO?

Do insiders & institutionals believe in COG or KOO?

Summary

How does Cambridge Cognition compare to Renalytix?

Is COG or RENX more profitable?

Which has more volatility & risk, COG or RENX?

Do insiders and institutionals hold more shares of COG or RENX?

Which has better valuation and earnings, COG or RENX?

Does the media favor COG or RENX?

Do analysts prefer COG or RENX?

Summary

How does Cambridge Cognition compare to Induction Healthcare Group?

Which has more risk and volatility, INHC or COG?

Does the media favor INHC or COG?

Do analysts prefer INHC or COG?

Is INHC or COG more profitable?

Which has stronger valuation and earnings, INHC or COG?

Do insiders and institutionals believe in INHC or COG?

Summary

How does Cambridge Cognition compare to Feedback?

Do analysts rate COG or FDBK?

Which has better earnings & valuation, COG or FDBK?

Is COG or FDBK more profitable?

Which has more risk and volatility, COG or FDBK?

Do insiders and institutionals hold more shares of COG or FDBK?

Does the media favor COG or FDBK?

Summary

How does Cambridge Cognition compare to IQ-AI?

Do analysts prefer IQAI or COG?

Which has higher valuation & earnings, IQAI or COG?

Do insiders & institutionals have more ownership in IQAI or COG?

Is IQAI or COG more profitable?

Does the media favor IQAI or COG?

Which has more volatility & risk, IQAI or COG?

Summary

Media Sentiment Over Time

COG vs. The Competition

Cambridge Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools